1-4 of 4
Christoph Mundhenke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P1-02-26: Biomarkers in metastatic breast cancer with brain metastases – a subanalysis of matched tumor samples of the BMBC registry

Free
Elena Laackmann, Kerstin Riecke, Sivaramakrishna Rachakonda, Volkmar Müller, Isabell Witzel, Marcus Schmidt, Klaus Junker, Peter A. Fasching, Mustafa Aydogdu, Leticia Oliveira-Ferrer, Paul Jank, Kristina Lübbe, Maria M. Karsten, Thomas Karn, Patricia von Kroge, Julia Teply-Szymanski, Thomas Decker, Martin Peters, Akira Hattesohl, Marion van Mackelenbergh, Marc Thill, Uta Ringsdorf, Anika Pehl, Christoph Mundhenke, Tanja Fehm, Julia Rey, Bärbel Felder, Sibylle Loibl, Carsten Denkert, Elena Laakmann
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-02-26.
https://doi.org/10.1158/1557-3265.SABCS24-P1-02-26
Published: 13 June 2025
View articletitled, Abstract P1-02-26: Biomarkers in metastatic breast cancer with brain metastases – a subanalysis of matched tumor samples of the BMBC registry
Journal Articles

Abstract LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study

Free
Sibylle Loibl, Marc Thill, Julia Rey, Beate Rautenberg, Vesna Bjelic-Radisic, Thomas Decker, Joachim Rom, Matthias Kögel, Kristina Lübbe, Axel Nacke, Nader Hirmas, Marianne Just, Volkmar Müller, Renu Buss-Steidle, Jürgen Terhaag, Christoph Mundhenke, Carsten Denkert, Johannes Holtschmidt1, Marcus Schmidt
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): LB1-03.
https://doi.org/10.1158/1557-3265.SABCS24-LB1-03
Published: 13 June 2025
View articletitled, Abstract LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study
Journal Articles

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Free
Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Pérez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer, Christian F. Singer, Sara Hurvitz, Laura García Estévez, Peter A. van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian D. Vogl, Dalila Sellami, Carlos L. Arteaga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (10): 2975–2987.
https://doi.org/10.1158/1078-0432.CCR-18-3160
Published: 15 May 2019
View articletitled, A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Open the PDF for A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) in another window
Includes: Supplementary data
Journal Articles

Tissue Examination to Monitor Antiangiogenic Therapy: A Phase I Clinical Trial with Endostatin

Free
Christoph Mundhenke, James P. Thomas, George Wilding, Fred T. Lee, Fred Kelzc, Rick Chappell, Rosemary Neider, Linda A. Sebree, Andreas Friedl
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (11): 3366–3374.
Published: 01 November 2001
View articletitled, Tissue Examination to Monitor Antiangiogenic Therapy: A Phase I Clinical Trial with Endostatin
Open the PDF for Tissue Examination to Monitor Antiangiogenic Therapy: A Phase I Clinical Trial with Endostatin in another window